US4289689A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Preparation of homogeneous human fibroblast interferon
Assignee: Hoffmann La Roche Inc
•
Filing: 1980-06-19
•
Granted: 1981-09-15
•
Expires: 2000-06-19
Abstract
Abstract Human fibroblast interferon has been purified to homogeneity by use of a novel procedure combining affinity chromatography and high pressure liquid chromatography (HPLC).
Inventors
- 👤 Heinz-Jurgen Friesen
- 👤 Sidney Pestka
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 06:53
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/565; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
165 words
A process for producing human fibroblast interferon as a homogeneous protein which process comprises the following steps in combination: A. passing an aqueous solution of human fibroblast interferon in an impure state through an affinity chromatography column so as to absorb said interferon onto said column and thereafter eluting said interferon from said column and obtaining said interferon in selected fractions of said eluate in a state of enhanced purity; and B. passing the selected said interferon fractions obtained in Step A through one or more buffer equilibrated hydrocarbon bonded silica matrix column under high pressure liquid chromatography conditions wherein said hydrocarbon is selected from the group consisting of cyclohexyl, phenyl, diphenyl, octyl, octadecyl and cyanopropyl, to absorb said interferon onto said column and thereafter eluting said interferon from said column with a gradient of an acidic aqueous buffered mixture of water miscible solvents and obtaining interferon as a single distinct peak in selected fractions of said eluate in the state of a homogeneous protein.
Claim 2
Dependent Claim
165 words
A process for producing human fibroblast interferon as a homogeneous protein which process comprises the following steps in combination: A. passing an aqueous solution of human fibroblast interferon in an impure state through an affinity chromatography column so as to absorb said interferon onto said column and thereafter eluting said interferon from said column and obtaining said interferon in selected fractions of said eluate in a state of enhanced purity; and B. passing the selected said interferon fractions obtained in Step A through one or more buffer equilibrated hydrocarbon bonded silica matrix column under high pressure liquid chromatography conditions wherein said hydrocarbon is selected from the group consisting of cyclohexyl, phenyl, diphenyl, octyl, octadecyl and cyanopropyl, to absorb said interferon onto said column and thereafter eluting said interferon from said column with a gradient of an acidic aqueous buffered mixture of water miscible solvents and obtaining interferon as a single distinct peak in selected fractions of said eluate in the state of a homogeneous protein.
Claim 3
Dependent Claim
67 words
The process of claim 1 wherein said affinity chromatography column is a Concanavalin A-Sepharose column; said high pressure liquid chromatography is carried out on a cyclohexyl bonded silica matrix column using as eluent a pyridine-formic acid-isopropanol solution gradient with increasing concentrations of n-butanol followed by passing the pooled active fractions through an octyl bonded silica matrix column using the same elution conditions as for the cyclohexyl column.
Claim 4
Dependent Claim
42 words
The process of claim 2 wherein said initial buffer composition in said high pressure liquid chromatography steps is pyridine 8%, formic acid 8% and iso-propanol 20% and said final buffer composition is pyridine 8%, formic acid 8, isopropanol 25% and n-butanol 20%.
Claim 5
Dependent Claim
44 words
The process of claim 1 wherein said affinity chromatography column is a Blue Dextran Sepharose column; said high pressure liquid chromatography is carried out on an octyl bonded silica matrix column using as eluent a pyridine-formic acid-iso-propanol-n-butanol solution gradient with increasing concentrations of n-butanol.
Claim 6
Dependent Claim
43 words
The process of claim 4 wherein said initial buffer composition in said high pressure liquid chromatography step is pyridine 8%, formic acid 8%, iso-propanol 20% and n-butanol 3.3% and said final buffer composition is pyridine 8%, formate 8%, iso-propanol 25% and n-butanol 20%.
Claim 7
Dependent Claim
40 words
The process of claim 4 wherein the pooled active fractions eluted from said octyl bonded silica matrix column is rechromatographed on a cyanopropyl bonded silica matrix column using as eluent a pyridine-formic acid-n-propanol solution gradient with increasing concentrations of n-propanol.
Claim 8
Dependent Claim
33 words
The process of claim 6 wherein said initial buffer composition is 8% pyridine, 8% formic acid and 0% n-propanol and said final buffer composition is pyridine 8%, formic acid 8% and 40% n-propanol.
Claim 9
Dependent Claim
42 words
The process of claim 4 wherein said initial buffer composition in said high pressure liquid chromatography step is pyridine 8%, formic acid 8% and iso-propanol 20% and said final buffer composition is pyridine 8, formic acid 8, iso-propanol 25% and n-butanol 20%.
Claim 10
Dependent Claim
43 words
The process of claim 6 wherein the pooled active fractions from said cyanopropyl bonded silica matrix column is passed through said column a second time and the pooled active fractions from said second passage are passed through a diphenyl bonded silica matrix column.
Claim 11
Dependent Claim
58 words
The process of claim 1 wherein said human fibroblast interferon is harvested from a serum free preparation, said affinity chromatography column is a Blue Sepharose 4B column and said high pressure liquid chromatography is carried out on an octyl bonded silica matrix using as eluent a step gradient of n-propanol, in a constant mixture of aqueous pyridine-formic acid.
Claim 12
Dependent Claim
35 words
The process of claim 10 wherein said step gradient of n-propanol consists of 0% for ten minutes, 30% for 40 minutes and 32% for 40 minutes wherein said interferon elutes between 80 and 90 minutes.
References Cited (Backward Citations)
US3699222A
Cited
US3144390A
Cited
US3265581A
Cited
US3385757A
Cited
US3414651A
Cited
US3256152A
Cited
US3548053A
Cited
US3560611A
Cited
US3652538A
Cited
US3804826A
Cited
US3773924A
Cited
US3845033A
Cited
US3800035A
Cited
US3948886A
Cited
US3970749A
Cited
US4061538A
Cited
US4041152A
Cited
US3910824A
Cited
US4130641A
Cited
US3981991A
Cited
US4017600A
Cited
US3975344A
Cited
US4060457A
Cited
US4144126A
Cited
US4100150A
Cited
GB1534812A
Cited
US4168261A
Cited
US4038139A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-09-14 | 1985-03-16 | 1985-09-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-09-14 | 1989-03-16 | 1989-09-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-09-14 | 1993-03-16 | 1993-09-15 | $7700.00 | Window Closed / Lapsed |